These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20947927)

  • 1. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
    Kim SJ; Kim K; Do YR; Bae SH; Yang DH; Lee JJ
    Jpn J Clin Oncol; 2011 Mar; 41(3):353-7. PubMed ID: 20947927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
    Minarik J; Pika T; Bacovsky J; Langova K; Scudla V
    Br J Haematol; 2012 Oct; 159(1):111-3. PubMed ID: 22816982
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
    Aoki T; Nishiyama T; Imahashi N; Kitamura K
    Jpn J Clin Oncol; 2011 Jul; 41(7):876-81. PubMed ID: 21616919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
    Vickrey E; Allen S; Mehta J; Singhal S
    Cancer; 2009 Jan; 115(1):229-32. PubMed ID: 19090004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib and bilateral herpes zoster.
    di Meo N; Bergamo S; Dondas A; Trevisan G
    Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
    Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
    J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
    Pour L; Adam Z; Buresova L; Krejci M; Krivanova A; Sandecka V; Zahradova L; Buchler T; Vorlicek J; Hajek R
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):151-3. PubMed ID: 19406726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
    Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
    Dasanu CA; Alexandrescu DT
    J Oncol Pharm Pract; 2010 Dec; 16(4):266-8. PubMed ID: 19965947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
    Varettoni M; Vassallo C; Borroni G; Mangiacavalli S; Zappasodi P; Rosso R; Lazzarino M; Corso A
    Ann Hematol; 2007 Apr; 86(4):301-2. PubMed ID: 17131123
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
    Hasegawa Y; Kawahara F; Nagai H; Hirose T; Imai Y; Ishiguro T; Chou T
    Rinsho Ketsueki; 2009 Jun; 50(6):488-94. PubMed ID: 19571509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
    Kim SJ; Kim K; Kim BS; Lee HJ; Kim H; Lee NR; Nam SH; Kwon JH; Kim HJ; Sohn SK; Won JH; Lee JH; Suh C; Yoon SS; Kim HJ; Kim I; Do YR; Lee WS; Joo YD; Shin HJ;
    Clin Lymphoma Myeloma; 2008 Aug; 8(4):237-40. PubMed ID: 18765311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.
    Guo H; Mao J; Qian X; Sun C; Sun H
    J Altern Complement Med; 2011 Nov; 17(11):985-6. PubMed ID: 22087609
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
    Chanan-Khan A; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Neuwirth R; Anderson KC; Richardson PG
    J Clin Oncol; 2008 Oct; 26(29):4784-90. PubMed ID: 18711175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
    Heider U; Rademacher J; Kaiser M; Kleeberg L; von Metzler I; Sezer O
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):134-7. PubMed ID: 20371447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
    Wu KL; van Wieringen W; Vellenga E; Zweegman S; Lokhorst HM; Sonneveld P
    Haematologica; 2005 Jul; 90(7):996-7. PubMed ID: 15996946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
    Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.